NASDAQ:ENTO Entero Therapeutics (ENTO) Stock Price, News & Analysis $2.28 +0.13 (+6.05%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.20 -0.08 (-3.51%) As of 08/29/2025 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Entero Therapeutics Stock (NASDAQ:ENTO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Entero Therapeutics alerts:Sign Up Key Stats Today's Range$1.97▼$2.2850-Day Range$1.09▼$2.2852-Week Range$0.84▼$2.78Volume117,012 shsAverage Volume5.25 million shsMarket Capitalization$3.63 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida. Read More Receive ENTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Entero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ENTO Stock News HeadlinesEntero Therapeutics files to sell 4.95M shares of common stock for holdersAugust 26, 2025 | msn.comEntero Therapeutics Inc trading halted, news pendingAugust 16, 2025 | msn.comTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predicted it all. Even crazier, this secret accurately called every major financial event in recent history … Now it's signaling something very scary is about to hit the market again … | Weiss Ratings (Ad)Entero Therapeutics stock falls after announcing reverse stock splitAugust 14, 2025 | investing.comEntero Therapeutics, Inc. Announces Reverse Stock Split | ENTO Stock NewsAugust 14, 2025 | gurufocus.comEntero Therapeutics regains Nasdaq compliance after annual meetingJuly 9, 2025 | investing.comEntero Therapeutics Inc ENTOJune 20, 2025 | morningstar.comMEntero Therapeutics Delays 10-K FilingApril 1, 2025 | tipranks.comSee More Headlines ENTO Stock Analysis - Frequently Asked Questions How have ENTO shares performed this year? Entero Therapeutics' stock was trading at $1.8660 on January 1st, 2025. Since then, ENTO shares have increased by 22.2% and is now trading at $2.28. How were Entero Therapeutics' earnings last quarter? Entero Therapeutics, Inc. (NASDAQ:ENTO) announced its earnings results on Thursday, August, 14th. The company reported ($0.42) EPS for the quarter. When did Entero Therapeutics' stock split? Entero Therapeutics's stock reverse split before market open on Monday, August 18th 2025.A 1-3 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, August 17th 2025. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split. How do I buy shares of Entero Therapeutics? Shares of ENTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Entero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Entero Therapeutics investors own include CDT Equity (CDT), BIOLASE (BIOL), Cyclacel Pharmaceuticals (CYCC), Dare Bioscience (DARE), PMGC (ELAB), TRACON Pharmaceuticals (TCON) and Tempest Therapeutics (TPST). Company Calendar Last Earnings8/14/2025Today8/29/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ENTO Previous SymbolNASDAQ:ENTO CIK1604191 Webwww.enterothera.com Phone561-589-7020FaxN/AEmployees9Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.06 million Net MarginsN/A Pretax MarginN/A Return on Equity-1,063.82% Return on Assets-17.94% Debt Debt-to-Equity RatioN/A Current Ratio2.81 Quick Ratio2.81 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($3.96) per share Price / Book-0.58Miscellaneous Outstanding Shares1,590,000Free Float1,576,000Market Cap$3.63 million OptionableN/A Beta0.80 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:ENTO) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.